Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801
Por:
Espinosa, E, Berciano-Guerrero, MA, Muñoz-Couselo, E, Puértolas, T, Manzano, JL, Soria, A, De Miguel, PA, Crespo, G, Sanz, LG, Cerezuela-Fuentes, P, de la Rosa, CA, Majem, M, Castaño, AG, Berrocal, A, Arroyo, FRG, de la Borbolla, MR, Bellido, L, Martínez, JM, Fernández, LA, Carnicero, AM, Castro, RL, Rodríguez, AB, Lecumberri, MJ, Guzmán, JCV, Balea, BC, Rodríguez, JF, Bautista, JV, Pérez, VN, Mujika, K, Subias, MC, Hernández, B, Algarra, SM and Márquez-Rodas, I
Publicada:
1 may 2026
Ahead of Print:
1 nov 2025
Resumen:
PurposeAnti-PD-1-based immunotherapy and targeted therapies (TT) are the current standard of care for patients with advanced melanoma. However, some patients die in less than a year from diagnosis and others become long-survivors. An accurate description of systemic treatments and patients' characteristics of long-term survivors are needed to guide treatment decisions in clinical practice.MethodsGEM-1801 is a multi-cohort prospective study from the Spanish Multidisciplinary Melanoma Group that includes patients with resectable stage III or unresectable stage III/IV melanoma. Patients surviving at least 5 years and patients surviving less than 1 year since diagnosis were selected. Baseline characteristics and first and second-line systemic treatments are described and compared between groups.ResultsFrom Aug 2018 to Dec 2023, 60 patients with long-term survival and 216 patients with short-term survival were included. Long-term survivors received immunotherapy (65%), including anti-PD-1 in 86% and combination of an anti-PD-1 and anti-CTLA-4 in 14%; and TT (35%). The Objective Response Rate (ORR) was 76% for anti-PD-1, 80% for combination immunotherapy and 83% for TT. Short-term survivors received immunotherapy (58%), including anti-PD-1 (70%), anti-CTLA-4 (1%), and anti-PD-1 plus anti-CTLA-4 (29%); TT (36%); and chemotherapy (2%). ORR was 7% for anti-PD-1, 0% for anti-CTLA-4, 14% for combination immunotherapy, 53% for TT and 0% for chemotherapy.ConclusionsResponse to first or second-line systemic treatment may be a surrogate for long-term survival patients with advanced melanoma.Clinical trial identificationClinicaltrials.gov: NCT03605771
Filiaciones:
Espinosa, E:
Univ Autonoma Madrid, Hosp Univ La Paz, Sch Med, CIBERONC, Madrid, Spain
Berciano-Guerrero, MA:
Hosp Reg Univ HRU, Med Oncol Dept, Inst Invest Biomed Malaga IBIMA, Malaga, Spain
Muñoz-Couselo, E:
Hosp Univ Vall Hebron, Med Oncol Dept, Barcelona, Spain
Vall Hebron Inst Oncol VHIO, Barcelona, Spain
Puértolas, T:
Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain
:
H Germans Trias i Pujol, ICO Badalona, Inst Catalan Oncol, Med Oncol Dept, Badalona, Spain
Soria, A:
Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain
Crespo, G:
Hosp Univ Burgos, Med Oncol Dept, Burgos, Spain
Sanz, LG:
Hosp Univ Puerta Hierro, Med Oncol Dept, Madrid, Spain
Cerezuela-Fuentes, P:
Hosp Clin Univ Virgen Arrixaca, Inst Murciano Invest IMIB Arrixaca, Dept Cardiol, Murcia, Spain
de la Rosa, CA:
Hosp Univ Clin San Carlos, Med Oncol Dept, Madrid, Spain
Majem, M:
Hosp Santa Creu i St Pau, Med Oncol Dept, Barcelona, Spain
Castaño, AG:
Hosp Univ Marques Valdecilla, Med Oncol Dept, Santander, Spain
Berrocal, A:
Hosp Gen Univ Valencia, Med Oncol Dept, Valencia, Spain
Arroyo, FRG:
Complejo Hosp Univ Pontevedra, Med Oncol Dept, Pontevedra, Spain
de la Borbolla, MR:
Hosp Univ Valme, Med Oncol Dept, Seville, Spain
Bellido, L:
Hosp Univ Salamanca, Med Oncol Dept, SAL, Inst Invest Biomed Salamanca IB, Salamanca, Spain
Martínez, JM:
Hosp Univ Toledo, Med Oncol Dept, Toledo, Spain
Fernández, LA:
Hosp Universitari Parc Tauli Sabadell, Med Oncol Dept, Sabadell, Spain
Carnicero, AM:
Hosp San Pedro La Rioja, Med Oncol Dept, Logrono, Spain
Castro, RL:
Hosp Clin Univ Valladolid, Med Oncol Dept, Valladolid, Spain
Rodríguez, AB:
Hosp Son Llatzer, Med Oncol Dept, Palma De Mallorca, Spain
Guzmán, JCV:
Hosp Gen Ciudad Real, Dept Nucl Med, Ciudad Real, Spain
Balea, BC:
Hosp Lucus Augusti, Serv Med Nucl, Lugo, Spain
Rodríguez, JF:
Hosp Univ Rio Hortega, Med Oncol Dept, Valladolid, Spain
Bautista, JV:
Hosp Univ Virgen de las Nieves, Med Oncol Dept, Granada, Spain
Pérez, VN:
Hosp Univ Costa Sol, Med Oncol Dept, Marbella, Spain
Mujika, K:
Med Oncol Dept, Onkologikoa Fundazioa, Donosti, Spain
Subias, MC:
Hosp Clin Univ Lozano Blesa, Med Oncol Dept, Zaragoza, Spain
Algarra, SM:
Clin Univ Navarra, Med Oncol Dept, Pamplona, Spain
Márquez-Rodas, I:
Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain
Hosp Univ San Pedro Alcantara, Med Oncol Dept, Caceres, Spain
Hosp Univ Navarra, Med Oncol Dept, Pamplona, Navarra, Spain
Green Submitted, hybrid
|